Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
The Second Affiliated Hospital of Dalian Medical University
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07349225CT.gov Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07103408CT.gov A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06789796CT.gov a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuvonralimab (this asset) | The Second Affiliated Hospital of Dalian Medical University | P3 | BB · 66 |
| Benmelstobart | Yayi He | P4 | A |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| hs-20093 | Shanghai Hansoh Biomedical Co., Ltd | P3 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Tuvonralimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Autoimmune Pulmonary Disease Due To PD-1 Deficiency | — | P4 | BB · 65 |
| Melanoma | — | P4 | B · 59 |
| Colorectal Cancer | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tuvonralimab in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tuvonralimab-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →